Vector Science & Therapeutics Expands IP Portfolio to 15 Patent Filings

The company’s expanding intellectual property estate centers on the "last mile" of medical treatment: the physical and biological barriers between a therapeutic agent and its target. By prioritizing delivery mechanisms over individual molecules, Vector aims to overcome limitations such as poor gastrointestinal stability for peptides and the systemic toxicity often associated with conventional administration. CTO Tom Bachinski noted that the strategy focuses on engineering solutions that concentrate treatment at difficult-to-reach sites while reducing unnecessary exposure elsewhere in the body.

Vector’s portfolio now spans six primary domains, including deep-tissue transdermal delivery, opioid-sparing pain management, and localized pancreatic oncology treatments. These technologies often integrate multiple disciplines, combining drug formulation with hardware such as microneedles, catheters, and sensor-guided control systems. A recurring theme across these applications is the use of lyophilized formulations and point-of-care reconstitution, designed to ensure stability for sensitive biological agents at the moment of use. By diversifying its technology across these platforms, the company seeks to create multiple pathways for future licensing, clinical partnerships, and collaborative development in regenerative medicine and smart wound care.